Thiele NA1, Abboud KA2, Sloan KB3.
Eur J Med Chem. 2016 Aug 8;118:193-207. doi: 10.1016/j.ejmech.2016.04.037. Epub 2016 Apr 14.The development of iron chelators suitable for the chronic treatment of diseases where iron accumulation and subsequent oxidative stress are implicated in disease pathogenesis is an active area of research. The clinical use of the strong chelator N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid (HBED) and its alkyl ester prodrugs has been hindered by poor oral bioavailability and lack of conversion to the parent chelator, respectively. Read More